You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

  • Technology appraisal guidance
  • Reference number: TA218
  • Published:  23 March 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Myelodysplastic syndromes - azacitidine: consultee and commentator comments on the ACD

  • Myelodysplastic syndromes - azacitidine: Celgene

  • Myelodysplastic syndromes - azacitidine: MDS UK Patient Support Group

  • Myelodysplastic syndromes - azacitidine: Royal College of Nursing

  • Myelodysplastic syndromes - azacitidine: Royal College of Pathologists and the British Society for Haematology

  • Myelodysplastic syndromes - azacitidine: Royal College of Physicians on behalf of NCRI/RCP/RCR/ACP/JCCO

  • Myelodysplastic syndromes - azacitidine: Department of Health

  • Myelodysplastic syndromes - azacitidine: Decision Support Unit review of Celgene's response to the post appeal ACD


This page was last updated: 16 February 2011

Back to top